{"log_id": 357393276673615721, "direction": 0, "words_result_num": 42, "words_result": [{"probability": {"variance": 0, "average": 0.752644, "min": 0.752644}, "location": {"width": 57, "top": 340, "height": 27, "left": 692}, "words": "性"}, {"probability": {"variance": 0.067739, "average": 0.725849, "min": 0.425788}, "location": {"width": 155, "top": 372, "height": 29, "left": 1136}, "words": "环状苷配"}, {"probability": {"variance": 0, "average": 0.958719, "min": 0.958719}, "location": {"width": 27, "top": 379, "height": 29, "left": 1376}, "words": "类"}, {"probability": {"variance": 0, "average": 0.727512, "min": 0.727512}, "location": {"width": 25, "top": 409, "height": 29, "left": 326}, "words": "富"}, {"probability": {"variance": 0.048195, "average": 0.633658, "min": 0.368324}, "location": {"width": 324, "top": 409, "height": 29, "left": 594}, "words": "进行两水化成"}, {"probability": {"variance": 0.015353, "average": 0.82233, "min": 0.650769}, "location": {"width": 256, "top": 406, "height": 34, "left": 1152}, "words": "创的化成"}, {"probability": {"variance": 0, "average": 0.931603, "min": 0.931603}, "location": {"width": 75, "top": 443, "height": 32, "left": 276}, "words": "酸"}, {"probability": {"variance": 0.071042, "average": 0.618808, "min": 0.410319}, "location": {"width": 107, "top": 443, "height": 29, "left": 571}, "words": "福三"}, {"probability": {"variance": 0.000943, "average": 0.628427, "min": 0.597719}, "location": {"width": 128, "top": 443, "height": 27, "left": 907}, "words": "酸况"}, {"probability": {"variance": 0.002555, "average": 0.834414, "min": 0.783867}, "location": {"width": 48, "top": 443, "height": 27, "left": 1147}, "words": "然后"}, {"probability": {"variance": 0.000448, "average": 0.977382, "min": 0.947569}, "location": {"width": 134, "top": 612, "height": 34, "left": 242}, "words": "病毒活性"}, {"probability": {"variance": 0.017982, "average": 0.926281, "min": 0.518131}, "location": {"width": 1108, "top": 676, "height": 34, "left": 294}, "words": "恩曲他滨和富马酸替诺福韦二吡重:通过细胞培养评估恩由他滨和替诺福韦联合抗病毒活性"}, {"probability": {"variance": 0.023821, "average": 0.926409, "min": 0.40303}, "location": {"width": 596, "top": 713, "height": 34, "left": 240}, "words": "结果显示恩曲他滨和替诺福韦具有协同扶病效应"}, {"probability": {"variance": 0.010686, "average": 0.94657, "min": 0.362919}, "location": {"width": 1102, "top": 779, "height": 34, "left": 294}, "words": "恩曲他滨:在类淋已母细胞系、MAGI-CC5细胞系和外周血单核细中评估了恩曲他滨对实验"}, {"probability": {"variance": 0.007533, "average": 0.95562, "min": 0.586966}, "location": {"width": 1156, "top": 816, "height": 29, "left": 242}, "words": "室和临床分离的HTV-1病毒株的抗病毒活性,恩曲他滨的EC值在0.0013~0.64μM(0.00030.158"}, {"probability": {"variance": 0.014258, "average": 0.935617, "min": 0.503519}, "location": {"width": 1090, "top": 850, "height": 32, "left": 290}, "words": "mL)之间。在恩曲他滨与核苷逆转录酶抑制剂(阿巴卡、拉米夫定、司他夫定、扎西他滨"}, {"probability": {"variance": 0.020826, "average": 0.926516, "min": 0.367405}, "location": {"width": 1159, "top": 884, "height": 34, "left": 240}, "words": "齐多大定》、非核苷逆转录酶抑制剂(地拉韦定、依法韦伦,奈韦拉平)、蛋白酶制剂(安普那"}, {"probability": {"variance": 0.00733, "average": 0.960833, "min": 0.546829}, "location": {"width": 1156, "top": 919, "height": 34, "left": 242}, "words": "韦、奈非那韦、利托那韦、沙奎那韦)联合用药的试验中,显示有相加至协同作用:恩曲他滨在细"}, {"probability": {"variance": 0.018692, "average": 0.922858, "min": 0.412904}, "location": {"width": 1154, "top": 953, "height": 34, "left": 240}, "words": "胞培养中显示出对HV-1亚型A、B、C、D、E、G的抗病毒活性(EC值在0.0070.075μM之"}, {"probability": {"variance": 0.021616, "average": 0.914139, "min": 0.433651}, "location": {"width": 891, "top": 989, "height": 32, "left": 240}, "words": "间),井显示对HV-2有毒株特异性的活性(EC值在0.007~1.5日M之间)"}, {"probability": {"variance": 0.012151, "average": 0.944545, "min": 0.44288}, "location": {"width": 1092, "top": 1056, "height": 34, "left": 290}, "words": "富马酸替诺福韦二味酶:在类淋巴母细胞系、原代单核细胞/巨噬细胞和外周血淋已细胞中"}, {"probability": {"variance": 0.019697, "average": 0.928256, "min": 0.433316}, "location": {"width": 1156, "top": 1090, "height": 32, "left": 242}, "words": "估了替诺福韦对实验室和临床分离的门V1病毒株的抗病毒活性,替诺程书的ECm值在O.D4E.5"}, {"probability": {"variance": 0.0201, "average": 0.906911, "min": 0.439481}, "location": {"width": 1145, "top": 1127, "height": 32, "left": 244}, "words": "μM之间。在替诺福韦与核苷逆转录酶抑制刑(阿巴卡、去羟肌苷、拉米夫定、司他夫定,扎西"}, {"probability": {"variance": 0.017621, "average": 0.930608, "min": 0.378141}, "location": {"width": 1156, "top": 1161, "height": 32, "left": 237}, "words": "滨、齐多夫定、非逆转录酶抑制剂(地拉韦定、依法韦佗、奈韦拉平)和蛋白酶抑制剂(安普"}, {"probability": {"variance": 0.01281, "average": 0.936632, "min": 0.454958}, "location": {"width": 1140, "top": 1195, "height": 34, "left": 237}, "words": "型书、地那韦、杂非那韦、利托那韦和沙那韦)联合用药的试验中,显示有相加至协同作用"}, {"probability": {"variance": 0.015278, "average": 0.943493, "min": 0.461367}, "location": {"width": 1156, "top": 1232, "height": 34, "left": 240}, "words": "在细胞培养中替诺福韦显示出对HIV-1亚型A、B、C、D、E、F、G和0的抗病毒活性(EC值在0.52.2"}, {"probability": {"variance": 0.011327, "average": 0.940788, "min": 0.588773}, "location": {"width": 946, "top": 1264, "height": 34, "left": 244}, "words": "μM之间),并显示对HIV-2有毒株特异性的活性(EC值在1.65.5日M之间"}, {"probability": {"variance": 0.000258, "average": 0.985788, "min": 0.963302}, "location": {"width": 84, "top": 1330, "height": 32, "left": 235}, "words": "耐药性"}, {"probability": {"variance": 0.027558, "average": 0.884402, "min": 0.471371}, "location": {"width": 1102, "top": 1399, "height": 34, "left": 288}, "words": "志曲滨和富马诺福书二吡呋酯:在细胞培养中筛选出了对恩曲他滨及替诺福韦联合用药"}, {"probability": {"variance": 0.004022, "average": 0.970602, "min": 0.673907}, "location": {"width": 1129, "top": 1433, "height": 34, "left": 233}, "words": "敏感性下降的HV-1分离病毒株,对这些病毒株的基因型分析显示,病毒逆转录酶出现了M184V"}, {"probability": {"variance": 0.019922, "average": 0.917712, "min": 0.474611}, "location": {"width": 274, "top": 1467, "height": 32, "left": 233}, "words": "和/或K55R氨基酸替代"}, {"probability": {"variance": 0.020002, "average": 0.933464, "min": 0.430258}, "location": {"width": 1099, "top": 1531, "height": 36, "left": 288}, "words": "在一初行疗受试者中开展的临床试验(研究934》中,对从所有实抗病治疗失"}, {"probability": {"variance": 0.031262, "average": 0.886826, "min": 0.385951}, "location": {"width": 1122, "top": 1568, "height": 36, "left": 233}, "words": "败的试中离1毒株进行了耐药性分析,这些受试者在144周或提前终止用药时EIY"}, {"probability": {"variance": 0.007694, "average": 0.960127, "min": 0.573302}, "location": {"width": 1136, "top": 1602, "height": 34, "left": 240}, "words": "U大0/ml与法伦相关的药性变异发生率最高,且该变异在各治疗组之间的发"}, {"probability": {"variance": 0.01708, "average": 0.925462, "min": 0.474602}, "location": {"width": 1152, "top": 1632, "height": 38, "left": 235}, "words": "生率相近思由他滨富马酸诺福书二呋酯治疗组分离的19分析样本中观察到2例出现"}, {"probability": {"variance": 0.039593, "average": 0.867189, "min": 0.395482}, "location": {"width": 1154, "top": 1671, "height": 38, "left": 230}, "words": "M引4V氨基酸替代,而齐多定拉米夫定治疗分离的29例分析样本中观察到10例,该氨基酸替"}, {"probability": {"variance": 0.013148, "average": 0.943483, "min": 0.468636}, "location": {"width": 1143, "top": 1707, "height": 34, "left": 230}, "words": "代与恩曲他滨和拉关夫药性相关。研究934的144周过程中,对受试者进行标准基因型分析"}, {"probability": {"variance": 0.035369, "average": 0.844036, "min": 0.427642}, "location": {"width": 473, "top": 1742, "height": 36, "left": 233}, "words": "木检测到小病株中5生65R置换"}, {"probability": {"variance": 0.011907, "average": 0.945859, "min": 0.466425}, "location": {"width": 1102, "top": 1808, "height": 36, "left": 283}, "words": "恩曲他滨通过细地培养和在人体内筛选到了对恩曲他滨产生耐药性的HIV-1病毒株。对这些"}, {"probability": {"variance": 0.020505, "average": 0.928225, "min": 0.372642}, "location": {"width": 1143, "top": 1842, "height": 36, "left": 226}, "words": "病毒的基因型分析显示其对恩曲滨敏感性降低与日IV-1逆转示酶基因上184位点的密码子发"}, {"probability": {"variance": 0.013749, "average": 0.928085, "min": 0.521752}, "location": {"width": 882, "top": 1877, "height": 34, "left": 230}, "words": "生碱基置换有关,该置换导致甲硫氨酸被氨酸或异亮氨酸(M184V/1)替代"}, {"probability": {"variance": 0.020013, "average": 0.853202, "min": 0.711736}, "location": {"width": 45, "top": 2105, "height": 29, "left": 1328}, "words": "29"}], "language": 3}